Armistice Capital LLC recently announced the acquisition of new stake in RVL Pharmaceuticals plc (NASDAQ:RVLP). This fresh investment now brings its stake to 10.72% valued currently at $4.27 million.
With over 4.24 million RVL Pharmaceuticals plc (RVLP) shares trading Tuesday and a closing price of $0.11 on the day, the dollar volume was approximately $0.47 million. The shares have shown a negative half year performance of -90.67% and its price on 09/12/23 gained nearly 9.55%. Currently, there are 99.37M common shares owned by the public and among those 83.71M shares have been available to trade.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Insiders at the company have transacted a total of 10 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 3 of these insider trades were purchases, accounting for 120,000 shares. Insider sales of the common stock occurred on 7 occasions, with total insider shares sold totaling 3,129,225 shares.
The top 3 mutual fund holders in RVL Pharmaceuticals plc are Meridian Contrarian Fund, SEB Concept Biotechnology Fund, and Vanguard Extended Market Index Fu. Meridian Contrarian Fund owns 1.51 million shares of the company’s stock, all valued at over $0.6 million. The company sold -0.12 million shares recently to bring their total holdings to about 1.52% of the shares outstanding. Vanguard Extended Market Index Fu now owns shares totaling to 0.23% of the shares outstanding.
Shares of RVL Pharmaceuticals plc (NASDAQ: RVLP) opened at $0.113, up $0.01 from a prior closing price of $0.10. However, the script later moved the day high at 0.1179, up 9.55%. The company’s stock has a 5-day price change of -17.54% and -86.89% over the past three months. RVLP shares are trading -89.76% year to date (YTD), with the 12-month market performance down to -95.38% lower. It has a 12-month low price of $0.09 and touched a high of $2.99 over the same period. RVLP has an average intraday trading volume of 1.75 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -28.73%, -66.77%, and -87.34% respectively.
Institutional ownership of RVL Pharmaceuticals plc (NASDAQ: RVLP) shares accounts for 49.90% of the company’s 99.37M shares outstanding. Mutual fund holders own 32.53%, while other institutional holders and individual stakeholders account for 66.59% and 2.46% respectively.
It has a market capitalization of $12.53M and a beta (3y monthly) value of 1.04. The earnings-per-share (ttm) stands at -$0.70. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.02% over the week and 25.63% over the month.
Analysts forecast that RVL Pharmaceuticals plc (RVLP) will achieve an EPS of -$0.09 for the current quarter, -$0.09 for the next quarter and -$0.34 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.11 while analysts give the company a high EPS estimate of -$0.06. Comparatively, EPS for the current quarter was -$0.16 a year ago. Earnings per share for the fiscal year are expected to increase by 53.20%, and 35.80% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate RVL Pharmaceuticals plc (RVLP) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the RVLP, a number of firms have released research notes about the stock. Jefferies stated their Hold rating for the stock in a research note on October 21, 2022, with the firm’s price target at $2.50.
